1017 related articles for article (PubMed ID: 12702569)
1. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
2. Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059.
Pathania AS; Joshi A; Kumar S; Guru SK; Bhushan S; Sharma PR; Bhat WW; Saxena AK; Singh J; Shah BA; Andotra SS; Taneja SC; Malik FA; Kumar A
Apoptosis; 2013 Dec; 18(12):1561-73. PubMed ID: 23948751
[TBL] [Abstract][Full Text] [Related]
3. GSK3β inhibition is involved in the neuroprotective effects of cyclin-dependent kinase inhibitors in neurons.
de la Torre AV; Junyent F; Folch J; Pelegrí C; Vilaplana J; Auladell C; Beas-Zarate C; Pallàs M; Verdaguer E; Camins A
Pharmacol Res; 2012 Jan; 65(1):66-73. PubMed ID: 21875668
[TBL] [Abstract][Full Text] [Related]
4. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals.
O'Gorman DM; McKenna SL; McGahon AJ; Knox KA; Cotter TG
Leukemia; 2000 Apr; 14(4):602-11. PubMed ID: 10764145
[TBL] [Abstract][Full Text] [Related]
5. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.
Rahmani M; Anderson A; Habibi JR; Crabtree TR; Mayo M; Harada H; Ferreira-Gonzalez A; Dent P; Grant S
Blood; 2009 Nov; 114(20):4507-16. PubMed ID: 19773546
[TBL] [Abstract][Full Text] [Related]
6. Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
Champelovier P; El Atifi M; Pautre V; Rostaing B; Berger F; Seigneurin D
Exp Hematol; 2008 Jan; 36(1):28-36. PubMed ID: 17949889
[TBL] [Abstract][Full Text] [Related]
7. PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway.
Moon DO; Park C; Heo MS; Park YM; Choi YH; Kim GY
Int Immunopharmacol; 2007 Jan; 7(1):36-45. PubMed ID: 17161815
[TBL] [Abstract][Full Text] [Related]
8. Beta-sitosterol-induced-apoptosis is mediated by the activation of ERK and the downregulation of Akt in MCA-102 murine fibrosarcoma cells.
Moon DO; Lee KJ; Choi YH; Kim GY
Int Immunopharmacol; 2007 Aug; 7(8):1044-53. PubMed ID: 17570321
[TBL] [Abstract][Full Text] [Related]
9. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Furuya F; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors.
Mohapatra S; Chu B; Zhao X; Djeu J; Cheng JQ; Pledger WJ
Int J Biochem Cell Biol; 2009 Mar; 41(3):595-602. PubMed ID: 18708158
[TBL] [Abstract][Full Text] [Related]
13. 3,3'-Diindolylmethane exhibits antileukemic activity in vitro and in vivo through a Akt-dependent process.
Gao N; Cheng S; Budhraja A; Liu EH; Chen J; Chen D; Yang Z; Luo J; Shi X; Zhang Z
PLoS One; 2012; 7(2):e31783. PubMed ID: 22363731
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of ZD1839 (Iressa)-induced apoptosis in human leukemic U937 cells.
Moon DO; Kim MO; Lee JD; Choi YH; Lee MK; Kim GY
Acta Pharmacol Sin; 2007 Aug; 28(8):1205-14. PubMed ID: 17640484
[TBL] [Abstract][Full Text] [Related]
15. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
16. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
[TBL] [Abstract][Full Text] [Related]
17. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.
Tabe Y; Jin L; Tsutsumi-Ishii Y; Xu Y; McQueen T; Priebe W; Mills GB; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
Cancer Res; 2007 Jan; 67(2):684-94. PubMed ID: 17234779
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induction of human leukemia cells by Streptomyces sp. SY-103 metabolites through activation of caspase-3 and inactivation of Akt.
Jeong SY; Han MH; Jin CY; Kim GY; Choi BT; Nam TJ; Kim SK; Choi YH
Int J Mol Med; 2010 Jan; 25(1):31-40. PubMed ID: 19956899
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
20. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
